Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.63 |
| ▸ | GPR139 | Q6DWJ6 | 2/20 | 0.62 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | NPC1 | O15118 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23122282 | 1.00 | MAPT (0.63) | MAPTGPR139HPGDALDH1A1KMT2A | |
| SCHEMBL31618280 | 1.00 | MAPT (0.63) | MAPTGPR139HPGDALDH1A1KMT2A | |
| SCHEMBL28310682 | 0.86 | MAPT (0.69) | MAPTGPR139HPGDALDH1A1KMT2A | |
| SCHEMBL23123075 | 0.84 | L3MBTL1 (0.54) | GPR139HPGDALDH1A1HTTL3MBTL1 | |
| SCHEMBL23123078 | 0.84 | L3MBTL1 (0.54) | GPR139HPGDALDH1A1HTTL3MBTL1 | |
| SCHEMBL9953212 | 0.84 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1NPSR1POLB | |
| SCHEMBL10066478 | 0.84 | ALDH1A1 (0.60) | ALDH1A1KMT2AMEN1NPSR1POLB | |
| SCHEMBL12975787 | 0.83 | MAPT (0.65) | MAPTGPR139HPGDALDH1A1KMT2A | |
| SCHEMBL19285674 | 0.83 | GPR139 (0.66) | MAPTGPR139HPGDALDH1A1KMT2A | |
| SCHEMBL7204764 | 0.83 | MAPT (0.65) | MAPTGPR139HPGDALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1212056-B1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | US GOV HEALTH & HUMAN SERV (US) | 2005-12-07 | — | — | EP | claimed |
| EP-1212056-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2002-06-12 | — | — | EP | claimed |
| US-20020002144-A1 | Methods and compositions for bisubstrate inhibitors of acetyltransferases | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2002-01-03 | — | — | US | claimed |
| WO-2001012185-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-02-22 | — | — | WO | claimed |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-07-29 | — | — | US | disclosed |
| WO-2025119351-A1 | GPR139 AGONIST | 深圳湾实验室 | 2025-06-12 | — | — | WO | disclosed |
| EP-4031552-B1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICALS CO (JP) | 2024-11-06 | — | — | EP | disclosed |
| CN-117003744-A | Five-membered and six-membered compound, intermediate, preparation method, composition and application | 厦门市博瑞来医药科技有限公司 | 2023-11-07 | — | — | CN | disclosed |
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-01-26 | — | — | US | disclosed |
| EP-4031552-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2022-07-27 | — | — | EP | disclosed |
| CN-114728975-A | Azole-fused pyridazin-3 (2H) -one derivatives | 武田药品工业株式会社 | 2022-07-08 | — | — | CN | disclosed |
| WO-2021055326-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2021-03-25 | — | — | WO | disclosed |
| EP-1212056-B1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | US GOV HEALTH & HUMAN SERV (US) | 2005-12-07 | — | — | EP | disclosed |
| EP-1212056-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2002-06-12 | — | — | EP | disclosed |
| US-20020002144-A1 | Methods and compositions for bisubstrate inhibitors of acetyltransferases | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, DEPARTMENT OF HEALTH & HUMAN SERVICES (US) | 2002-01-03 | — | — | US | disclosed |
| WO-2001012185-A1 | METHODS AND COMPOSITIONS FOR BISUBSTRATE INHIBITORS OF ACETYLTRANSFERASES | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2001-02-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230028114-A1 | AZOLE-FUSED PYRIDAZIN-3(2H)-ONE DERIVATIVES | GPR139, GPR119, GPR39 | MAPT 4369/4885GPR139 1/4885HPGD 3205/4885 |
| US-12370192-B2 | Azole-fused pyridazin-3(2H)-one derivatives | GPR139, GPR119, GPR39 | MAPT 4369/4885GPR139 1/4885HPGD 3205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.